Ozempic sell-off: What is Goldman saying about CSL and ResMed shares?

CSL and ResMed shares were hammered yesterday. Was it an overreaction?

| More on:
Shot of a young scientist looking stressed out while working on a computer in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) and ResMed Inc (ASX: RMD) shares were under the pump on Thursday.

Both healthcare giants sank deep into the red after the market panicked over the results of another trial of the weight loss drug Ozempic. This time the wonder-drug was being trialled for the treatment of chronic kidney disease.

Ozempic delivered such strong results that the Independent Data Monitoring Committee recommended that it end as it was no longer necessary or moral to continue the study with a placebo arm.

CSL and ResMed shares fall: should you be concerned?

Goldman Sachs has been looking into the implications of the trial results on both CSL and ResMed. It highlights two areas of concern. The first is:

There is a direct link to CSL through the Vifor segment (potentially a direct earnings impact for a company which sells drugs to the kidney disease/dialysis populations, but also potential consequences for the carrying value of the business itself, which is comprised almost entirely of intangible assets and goodwill).

Another concern is that as the use cases for Ozempic grow, so too does the potential for governments and insurance companies to offer reimbursements or coverage. The high cost of Ozempic was expected to hold it back from true mass adoption, but this could potentially change. It adds:

Each positive outcome trial from NOVO or LLY broadens the potential utility of the GLP-1/GIP receptor agonist class and strengthens the argument that coverage/reimbursement should be expanded.

As we wrote here, the current c.US$1k list price of these drugs is prohibitive to the majority of those unable to secure coverage, and that is unlikely to change in the near-term. As/when payor access improves, the degree of potential threat increases for those companies positively levered to weight/diabetes/cardiovascular risk etc (e.g. RMD, FPH).

Sales impact

Fortunately for CSL, it has a very large business and multiple revenue streams. As a result, the broker estimates that just 7% to 8% of its overall revenue would be subject to the impacts of Ozempic's rise.

This could arguably make yesterday's CSL share price sell down a bit of an overreaction.

As for ResMed, the broker isn't concerned about the news and continues to believe that both Ozempic and ResMed's sleep treatment devices can co-exist. As a result, it continues to forecast strong long-term growth from ResMed and sees lots of value in its shares. It adds:

In our view, these concerns have been more than adequately priced into RMD shares, and we continue to reiterate our Buy rating. We remain Neutral-rated on CSL.

Goldman has a buy rating and $33 price target on ResMed's shares (offering 49% upside), and a neutral rating and $296.00 price target on CSL's shares (offering 24% upside).

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »